节点文献

基于重链抗体的靶向c-Met的ADC药物:单剂量治疗肺腺癌大肿瘤（英文）

Design of heavy chain antibody-drug conjugates targeting c-Met to eradicate lung adenocarcinoma giant tumors with a single-dose

推荐 CAJ下载
PDF下载
不支持迅雷等下载工具，请取消加速工具后下载。

【作者】宁文静；刘涵；曾弘烨；秦晓静；许林；杨诗婷；曾治人；袁娜；祝珍珍；陈小青；许涛；陈奋天；张梦轩；唐济贤；陈永凯；陈远志；刘雪；罗文新；夏宁邵；

【Author】 Wenjing Ning;Han Liu;Hongye Zeng;Xiaojing Qin;Lin Xu;Shiting Yang;Zhiren Zeng;Na Yuan;Zhenzhen Zhu;Xiaoqing Chen;Tao Xu;Fentian Chen;Mengxuan Zhang;Jixian Tang;Yongkai Chen;Yuanzhi Chen;Xue Liu;Wenxin Luo;Ningshao Xia;State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University;National Institute of Diagnostics and Vaccine Development in Infectious Diseases, National Innovation Platform for Industry-Education Integration in Vaccine Research, the Research Unit of Frontier Technology of Structural Vaccinology of Chinese Academy of Medical Sciences, Xiamen University;

【通讯作者】陈远志;刘雪;罗文新;夏宁邵;

【机构】 State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University； National Institute of Diagnostics and Vaccine Development in Infectious Diseases, National Innovation Platform for Industry-Education Integration in Vaccine Research, the Research Unit of Frontier Technology of Structural Vaccinology of Chinese Academy of Medical Sciences, Xiamen University；

【摘要】 <正>Aberrant c-Met receptor activation is linked to various cancers,including lung, colon, and liver cancers, making it an important target for cancer therapy [1–4]. Current treatments primarily involve small molecule inhibitors and antibodies, but challenges such as suboptimal efficacy and side effects persist [5–7]. Recently, the focus has shifted toward large molecule drugs, such as monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates(ADCs), offering new cancer treatment options [8,9].更多还原

【关键词】肺腺癌； ADC； c-Met；靶向；剂量；抗体； colon； monoclonal； persist； offering；

【基金】 supported by the National Natural Science Foundation of China (32400779 and 82202500);the Science and Technology Planning Project of Fujian Province (2022L3080);the National Postdoctoral Program for Innovative Talents (BX20220189);the Fundamental Research Fund for the Central Universities (20720220006);the Science and Technology Planning Project of Xiang An Biomedicine Laboratory (2024XAKJ0102010 and 2023XAKJ0102041)

【文献出处】 Science Bulletin ,科学通报(英文版) , 编辑部邮箱 ,2025年13期

【分类号】R734.2
【下载频次】11

知网节下载

节点文献中：

本文链接的文献网络图示:

本文的引文网络

节点文献